Last reviewed · How we verify
Oral Colchicine in Argentina to Prevent Restenosis (ORCA)
The Oral treatment of Colchicine in Argentina (ORCA) trial is a prospective, randomized, multicenter trial to included 450 patients with indication for myocardial revascularization with PCI between a group to be treated with BMS plus oral colchicine (OC) for three months, which should be administered at the time of PCI, these patients they would receive 0.5 mg twice a day per 3 months compared to the other group of patients who will be treated exclusively with last generation of DES.
Details
| Lead sponsor | Centro de estudios en Cardiologia Intervencionista |
|---|---|
| Phase | PHASE4 |
| Status | COMPLETED |
| Enrolment | 410 |
| Start date | Thu Mar 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Apr 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Coronary Artery Disease
- Restenosis of Coronary Artery Stent
- Atherosclerosis
- Acute Coronary Syndrome
Interventions
- Colchicine
Countries
Argentina